Amlitelimab  (Synonyms: KY1005; SAR445229)

Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis^[1][2][3].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Amlitelimab (150 μg/mL) 抑制人 CD3 T 细胞的增殖^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized Human OX40 Ligand/TNFSF4 Protein (ECD, mFc Tag) can bind Amlitelimab. The EC₅₀ for this effect is 3.87 ng/mL.
• 
  Loaded OX40 Ligand/TNFSF4 (HEK293, His, HY-P70622) on AHC2 biosensor, can bind Amlitelimab with an affinity constant of <1.000E-11 M as determined in BLI assay.

• [1]. Ana Maria Lé, et al. OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics 2022, 14(12), 2753.

  [2]. Saghari M, et al. OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005. Clin Pharmacol Ther. 2022 May;111(5):1121-1132.  [Content Brief]

  [3]. Tkachev V, et al. Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med. 2017 Sep 20;9(408):eaan3085.  [Content Brief]